UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): December 21, 2006
SERACARE LIFE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
California 0-33045 33-0056054
------------------ ----------------------- --------------
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification No.)
375 West Street, West Bridgewater, MA 02379
- ------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (508) 580-1900
---------------
N/A
--------------------------------------------------------------------
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Section 7.01. Regulation FD Disclosure
As previously reported, on March 22, 2006, SeraCare Life Sciences, Inc., a
California corporation (the "Company"), filed a voluntary petition for
reorganization under chapter 11 of the United States Bankruptcy Code in the
United States Bankruptcy Court for the Southern District of California (the
"Bankruptcy Court").
On December 21, 2006, the Bankruptcy Court approved the Joint First Amended
Disclosure Statement of the Company and The Ad Hoc Equity Committee (the
"Disclosure Statement"). The Disclosure Statement provides information
concerning the Company's business, the Company's financial circumstances, and
describes the Company and the Ad Hoc Equity Committee's First Amended Joint Plan
of Reorganization (the "Plan") for purposes of soliciting votes on the Plan. In
connection with the approval of the Disclosure Statement, the Bankruptcy Court
set February 15, 2007 at 10:00 a.m. as the date and time for a hearing on
confirmation and approval of the Plan.
The Company's bankruptcy case is No. 06-00510-11 (the "Bankruptcy Case").
Documents filed in connection with the Bankruptcy Case are accessible at the
Bankruptcy Court's Internet site, www.casb.uscourts.gov, through an account
obtained from Pacer Service Center at 1-800-676-6856. The information set forth
on the Bankruptcy Court's Internet site shall not be deemed to be a part of or
incorporated by reference into this Current Report on Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 28, 2006 SERACARE LIFE SCIENCES, INC.
By: /s/ Gregory A. Gould
---------------------------------
Gregory A. Gould
Chief Financial Officer